Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Gross Profit: 2012-2024

Historic Gross Profit for Ani Pharmaceuticals (ANIP) over the last 13 years, with Dec 2024 value amounting to $364.2 million.

  • Ani Pharmaceuticals' Gross Profit rose 57.67% to $134.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.6 million, marking a year-over-year increase of 52.23%. This contributed to the annual value of $364.2 million for FY2024, which is 19.28% up from last year.
  • As of FY2024, Ani Pharmaceuticals' Gross Profit stood at $364.2 million, which was up 19.28% from $305.3 million recorded in FY2023.
  • In the past 5 years, Ani Pharmaceuticals' Gross Profit ranged from a high of $364.2 million in FY2024 and a low of $115.5 million during FY2021.
  • Its 3-year average for Gross Profit is $282.4 million, with a median of $305.3 million in 2023.
  • Per our database at Business Quant, Ani Pharmaceuticals' Gross Profit declined by 15.39% in 2020 and then soared by 71.90% in 2023.
  • Yearly analysis of 5 years shows Ani Pharmaceuticals' Gross Profit stood at $121.3 million in 2020, then dropped by 4.77% to $115.5 million in 2021, then spiked by 53.73% to $177.6 million in 2022, then surged by 71.90% to $305.3 million in 2023, then grew by 19.28% to $364.2 million in 2024.